ABCL Rule of 40
Rule of 40 combines revenue growth and free cash flow margin in one quarterly score.
Rule of 40
2026 Q2
n/m
Not meaningful
Revenue growth context−76.3%
FCF margin context+587.4%
Why R40 is not meaningful yet
Capital expenditure and cash flow are too large relative to current revenue for the combined Rule of 40 score to be meaningful.
Quarter context
2025 Q4
Revenue $44.9M (+788.2% YoY). Capex $9.8M (0.2× revenue); FCF −$44.6M.
2026 Q1
Revenue $8.3M (+96.3% YoY). Capex $3.8M (0.5× revenue); FCF −$37.4M.
2026 Q2
Revenue $4.0M (−76.3% YoY). Capex $2.1M (0.5× revenue); FCF $23.8M.
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 8
Revenue
EPS
Free Cash Flow
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Healthcare Comparison
1 / 3
LLY · Rule of 40
2026 Q2 · latest
81.4✓ Passing
Growth +47.7%
FCF +33.8%
46
Q1
47
Q2
92
Q3
46
2025
Q4
71
Q1
81
2026
Q2
40
0
Mix
JNJ · Rule of 40
2026 Q2 · latest
35.4✗ Below 40
Growth +6.6%
FCF +28.8%
36
Q3
29
2024
Q4
19
Q1
18
Q2
40
Q3
31
2025
Q4
16
Q1
35
2026
Q2
40
0
Mix
ABBV · Rule of 40
2026 Q2 · latest
28.5✗ Below 40
Growth +10.2%
FCF +18.3%
39
Q3
50
2024
Q4
19
Q1
38
Q2
51
Q3
39
2025
Q4
36
Q1
28
2026
Q2
40
0
Mix
Latest Rule of 40: 0 (2026Q2); 0 pts YoY.